

A photograph of the Eiffel Tower in Paris, France, taken from a low angle on the Champ de Mars. The tower is silhouetted against a bright, hazy sunset sky. The foreground shows the checkered pattern of the Champ de Mars. The image is framed by two large, overlapping triangular shapes, one light blue and one yellow, that meet at the bottom.

11th International Workshop on Peritoneal Surface Malignancy

PRELIMINARY PROGRAM

SEPTEMBER 9-11, 2018

Maison de la Chimie,
Paris, France



www.psogi2018.com

Saturday, September 8th

16h00 - 18h00 **Registration**

Sunday, September 9th

07h30 **Registration**

08h15 **Welcome Remarks**

PH. Sugarbaker (USA) - O. Glehen (France) - D. Goéré (France) - M. Pocard (France)



08h30 **Colorectal and gastric free papers**

Chairmen: O. Glehen (France) - PH. Sugarbaker (USA)

> **CO01** - Combined liver and peritoneal resection with HIPEC for metastatic colorectal cancer: results of a worldwide analysis of 570 patients from the Peritoneal Surface Oncology Group International (PSOGI).

R. Lo Dico (France), M. Faron (France), D. Goéré (France), O. Glehen (France), Y. Yonemura (Japan), M. Pocard (France), W. Ceelen (Belgium), A. Sardi (USA), D. Baratti (Italy), G. Liberale (Belgium), A. Kartheuser (Belgium), I. De Hingh (The Netherlands), P. Sammartino (Italy), P. Sugarbaker (USA), B. Moran (UK), M. Robella (Italy), M. Hubner (Switzerland), M. Limbert (Portugal), L. Sideris (Canada), D. Morris (Australia).

> **CO02** - Mechanism and treatment strategy for peritoneal recurrence after curative gastric cancer surgery.

S. Murata, K. Takebayashi, T. Yamaguchi, S. Kaida, H. Kodama, H. Iida, K. Naomi, H. Maehira, H. Mori, T. Shimizu, E. Mekata, Y. Daigo, M. Tani (Japan).

> **CO03** - Effect of postoperative morbidity on survival after cytoreductive surgery (CRS) with heated intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis in a series of 734 cases.

C. Eveno, R. Schiavone, M. Pocard, M.J. Caballero, E. Gayat (France).

> **CO04** - Mutations of Ras/Raf-proto-oncogenes impair survival after cytoreductive surgery & HIPEC for peritoneal metastasis of colorectal origin.

M. Schneider (Switzerland), J. Eden (Switzerland), B. Pache (Switzerland), F. Lamingier (Austria), V. Lopez-Lopez (Spain), T. Steffen (Switzerland), M. Hübner (Switzerland), F. Kober (Austria), S. Roka (Austria), P. Cascales Campo (Spain), L. Roth (Switzerland), A. Gupta (Switzerland), A. Siebenhüner (Switzerland), G. Passot (France), V. Kepenekian (France), P. Gertsch (Switzerland), O. Glehen (France), K. Lehmann (Switzerland).

> **CO05** - Pharmacokinetic studies of intraperitoneal nanoparticles in patients with peritoneal metastases show EPIC as the optimal methodology for perioperative.

P. Sugarbaker, O. Stuart (USA).

09h20 In practice*Chairmen: R. Lo Dico (France) - Y. Yonemura (Japan)***1. Intraperitoneal chemotherapy: indications in gastric peritoneal metastases.***Speaker: J. Kitayama (Japan)***2. PIPAC: How I do it?***Speaker: M. Hübner (Switzerland)***09h50 Take home message***Evaluation of histological response to preoperative chemotherapy**Chairmen: F. Bibeau (France) - P. Sammartino (Italy)**Speaker: W. Solass (Germany)***10h00 BREAK - VISIT POSTERS AND EXHIBITS****10h30 Best communications session 1 - Free papers***O. Glehen (France), D. Goéré (France), M. Pocard (France)***> BC01 - HIPEC for gastro-intestinal neuroendocrine neoplasms: an propensity score matched analysis of all HIPEC centers in The Netherlands and Belgium.***N. Sluiter (The Netherlands), D. Croll (The Netherlands), M. Vriens (The Netherlands), I. De Hingh (The Netherlands), P. Hemmer (The Netherlands), A. Aalbers (The Netherlands), A. Bremers (The Netherlands), W. Ceelen (Belgium), A. D'hoore (Belgium), L. Schoonmade (The Netherlands), V. Coupé (The Netherlands), G. Kazemier (The Netherlands), J. Van Der Bilt (The Netherlands), J. Tuynman (The Netherlands).***> BC02 - Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for nonresectable peritoneal metastasis from gastric cancer.***M. Alyami, P.E. Bonnot, F. Mercier, L. Villeneuve, I. Bonnefoy, P. Jourdan-Enfer, N. Bakrin, O. Glehen (France).***> BC03 - A first in man study of direct injection of Bromelain and N-Acetylcysteine into recurrent pseudomyxoma peritonei of appendiceal origin.***S. Valle, J. Akhter, M. Power, D. Glenn, W. Liauw, D. Morris (Australia).***11h00 Recent results of the randomized clinical trials and futures for colorectal and gastric peritoneal metastases***Chairmen: M. Pocard (France) - S. Gonzales Moreno (Spain) - V. Verwaal (Denmark)***› PRODIGE 7 - F. Quenet (France)****› PROPHYLOCHIP - D. Goéré (France)****› COLOPEC - P.J. Tanis (The Netherlands)****› COMBATAC - P. Piso (Germany)****› GASTRIPEC - B. Rau (Germany)****› GASTRTICHIP - O. Glehen (France)**

PARALLEL SESSIONS

ROOM
10108h30 - 12h15 **Radiological consensus session***Organizing: A. Dohan (France), P. Rousset (France)***Consensus statement:**

- **Presentation of CT and MRI findings with surgical and pathological correlations**
 - Definition of a common lexicon of unequivocal imaging patterns of peritoneal metastases (PM), taking into account the pathology of the primary tumor: gastric, colorectal, appendiceal and ovarian cancer, pseudomyxoma and peritoneal mesothelioma.
 - Scoring method for radiological PCI to allow a reliable quantitative assessment of PM.
 - Definition of unresectable PM and lesion that may need surgical expertise to allow a useful qualitative description of PM.
 - Standardized radiological report based on an atlas/a guide to allow better patient selection for CRS +/- HIPEC.
- **Discussion for standardizing imaging protocols (MRI and CT).**

12h15 **LUNCH - VISIT POSTERS AND EXHIBITS**13h30 **Satellite Symposium:***sponsored by*  **gamida****Debates: Procedures for HIPEC: open/closed/laparoscopy***Chairmen: J. Esquivel (USA) - M. Pocard (France)***1. Pro open***Speaker: D. Bartlett (USA)***2. Pro closed***Speaker: O. Glehen (France)*14h30 **Selected videos***Chairmen: A. Nissan (Israël) - C. Arvieux (France)*

> **V1 - Approach to the porta hepaticus during cytoreductive surgery - technical considerations.**

Armando Sardi (USA).

> **V2 - i. urinary reconstructions after crs + hipec. ureter reconstructions.**

Pedro Barrios, Isabel Ramos, Oriol Crusellas, Domenico Sabia (Spain).

> **V3 - Technic to achieve optimal cytoreductive surgery in peritoneal carcinomatosis - techniques of systematic total peritonectomy.**

Kr Ashwin (India).

> **V4 - Circonférentiel pariétal et mésentérique complète peritonectomie avec co2 pneumatization.**

*Pedro Barrios, Isabel Ramos, Oriol Crusellas, Domenico Sabia (Spain).*PLENARY
ROOM

15h10 Take home message: Screening before HIPEC*Chairmen: H. Cashin (Sweden) - P. Rousset (France)**Speaker: C. Dromain (France)***15h30 Best communications session 2 - Free papers***Chairmen: O. Glehen (France), D. Goéré (France), M. Pocard (France)***> BC04 - Cytoreductive surgery and multivisceral small bowel transplantation.***T. Cecil, P. Allan, S. Reddy, G. Vrakas, H. Giele, F. Mohamed, A. Vaidya, B. Moran, P. Friend (UK).***> BC05 - Does hypertermic intraperitoneal chemotherapy has an additional benefit over cytoreduction alone in pseudomyxoma peritonei? A propensity score analysis of the PSOGI database.***S. Kusamura (Italy), E. Nizri (Italy), Y. Yonemura (Japan), P.H. Sugarbaker (USA) 4, B.J. Moran (UK), E.A. Levine (USA), D. Gore (France), F. Barretta (Italy), D.L. Morris (Australia), O. Glehen (France), A. Sardi (USA), P. Barrios (Spain), F. Quenet (France), L. Villeneuve (France), D. Baratti (Italy), M. Deraco (Italy).***> BC06 - Association between epidural analgesia and outcome in patients operated with curative intent of peritoneal carcinomatosis: a cohort study of 606 patients.***E. Gayat, M.J. Caballero, R. Schiavone, A. Mebazaa, M. Pocard, C. Eveno (France).***PARALLEL SESSION****14h30 Translational research and pre-clinical models for peritoneal disease***Chairmen: I. De Hingh (The Netherlands) - M. Pocard (France)***1. Animal model for PIPAC***Speaker: W. Ceelen (Belgium)***2. PMP4Cure an European network***Speaker: K. Flatmark (Norway)***3. Prophylaxis of peritoneal tumoral implants***Speaker: M. Pocard (France)***4. Free papers:****> CO06 - Early intra-abdominal adhesions: can we still pretend they won't spoil our closed-abdomed HIPEC?***M. Lotti, G. Panyor, N. Paderno, P. Calcagno, E.M. Vaterlini, C. Bertani, M. Marini, M. Giulii Capponi (Italy).***> CO08 - Biosynthetic mesh increases peritoneal metastasis growth in animal model, the biological mesh does not!***L. Guerry, M. Ullah, R. Kaci, M. Pocard, R. Lo Dico (France).***> CO09 - Novel treatment with intraperitoneal MOC31PE immunotoxin in colorectal peritoneal metastasis: long-term outcome from the ImmunoPeCa trial.***I.S. Frøysnes, Y. Andersson, S.G. Larsen, B. Davidson, J.M. Torset Øien, K.H. Olsen, K.E. Giercksky, L. Julsrud, Ø. Fodstad, S. Dueland, K. Flatmark (Norway).***> CO10 - Role of Liquid biopsy as a prognostic factor in Peritoneal Carcinomatosis. Preliminary results in a personalized cohort.***D. Cortes-Guiral, I. Lopez-Rojo, S. Olmedillas-Lopez, M. Garcia-Arranz, D. Garcia-Olmo (Spain).*

16h30 **Radiology and Translational Research - Free papers**

Chairmen: W. Ceelen (Belgium), A. Dohan (France)

> **CO17** - Narrow-band imaging improves detection of colorectal peritoneal metastases: a clinical study comparing advanced imaging techniques.
N. Sluiter, S. Vlek, W. Arthur, T. Brandsma, H. De Vet, N. Van Grieken, G. Kazemier, J. Tuynman (The Netherlands).

> **CO18** - MRI of Peritoneal Malignancy: 28 year Experience with Preoperative Evaluation and Surveillance MRI of Patients Undergoing CRS and HIPEC.

R. Low, R. Barone (USA).

> **CO19** - Whole-Body diffusion weighted MR-imaging (DW-MRI) to predict a complete resection in ovarian cancer patients; a pilot study.

M. Engbersen, I. Van 't Sant, C. Lok, D. Lambregts, W. Van Driel, R. Beets-Tan, M. Lahaye (The Netherlands).

> **CO20** - Accuracy of FDG-PET/CT for the selection of patients with colorectal peritoneal metastases undergoing cytoreductive surgery and heated intra-peritoneal chemotherapy.

M. Bock, O. Fisher, M. Kozman, N. Alzharani, S. Valle, M. Power, D. Glenn, D. Morris (Australia).

> **CO21** - Optical Imaging for peritoneal metastases detection in ovarian cancer.

G. Liberale, F. Pop, S. Vankerckhove, R. Barbieux, M. Galdon Gomez, D. Larsimont, V. Donckier, P. Bourgeois, I. Veys (Belgium).

17h20 **Keynote Lecture: BIG DATA - applications for clinical research**

Chairman: V. Verwaal (Denmark)

Speaker: JM. Bereder (France)

17h45 **Clinical cases "from the less to the more experienced surgeons"**

Chairmen: O. Sgarbura (France) - A. Bhatt (India)

PARALLEL SESSION

ROOM
10116h30 **Flash Pathology: from diagnosis to precision medicine***Organizing: F. Bibeau (France), P. Dartigues (France)*

Globet cell carcinoid: recent data from a complex entity. Impact on the treatment strategy.

Speaker: M. Taggart (USA).

> **CO11** - Prognostic value of Peritoneal Grading Regression Score (PRGS) in peritoneal metastasis: an exploratory analysis on registry data.

W. Solass, F. Kurtz, F. Struller, A. Staebler, H. Bösmüller, A. Königsrainer, F. Fend (Germany).

> **CO12** - Standardization of classification of PMP does not warrant standardization of interpretation: identifying the problem areas.

P. Dartigues (France), L. Van Velthuysen (The Netherlands), N. Carr (UK), F. Bibeau (France), R. Bradley (USA), K. Geisinger (USA), X. Gui (Canada), S. Isaac (France), J. Misdraji (USA), R. Pai (USA), J. Shia (USA), M. Taggart (USA), R. Yantiss (USA).

> **CO13** - Prognostic impact of primary side and RAS/RAF mutations on surgically treated peritoneal metastases from colorectal cancer.

D. Baratti, S. Kusamura, F. Perrone, M. Niger, F. Pietrantonio, M. Guaglio, M. Di Bartolomeo, M. Deraco (Italy).

> **CO14** - Nodal stage and RAS-mutations predict peritoneal recurrence after CRS/HIPEC in colorectal cancer patients.

E. Breuer (Switzerland), M.A. Schneider (Switzerland), J. Eden (Switzerland), B. Pache (Switzerland), T. Steffen (Switzerland), M. Hübner (Switzerland), L. Roth (Switzerland), A. Gupta (Switzerland), V. Kepenekian (France), L. Villeneuve (France), P. Gertsch (Switzerland), O. Glehen (France), K. Lehmann (Switzerland).

> **CO15** - Integrative analysis of transcriptomic and proteomic profiles of ascites provides insight into epithelial-mesenchymal-transition phenotype induced by paracrine signalling in colorectal peritoneal carcinomatosis.

J. Hendrikson, W.H. Ng, X. Qiu, J.W.S. Tan, N.B. Shannon, C.S. Chia, G.H.C. Tan, W. Tse, S.K. Sze, K.C. Soo, O.L. Kon, C.A.J. Ong, M.C.C. Teo (Singapore).

> **CO16** - How many tissue blocks are needed to reliably diagnose acellular mucin in the peritoneal cavity? A pilot study.

M. Al-Azzawi, B. Moran, T. Cecil, F. Mohamed, S. Dayal, N. Carr (UK).

Monday, September 10th

07h00 **Registration**

07h30 **Meet the professor**

1. CT assessment versus laparoscopic assessment of peritoneal metastases prior to CRS.

O. Glehen (France) - P. Rousset (France) - K. Van der Speeten (Belgium).

ROOM
201

2. Laparoscopic HIPEC: indications?

M. Alyami (France) - J. Esquivel (USA) - B. Rau (Germany).

ROOM
232

3. Management of parietal defect.

R. Lo Dico (France) - D. Morris (Australia) - G. Passot (France).

ROOM
233

4. Management of intraoperative hyperthermia.

V. Billard (France) - I. de Hingh (The Netherlands) - M. Pocard (France).

ROOM
234

5. Pathology and peritoneal malignancies.

F. Bibeau (France) - N. Carr (USA) - W. Solass (USA)

ROOM
269

08h30 **Peritoneal primary malignancies - Free papers**

Chairmen: EA. Levine (USA) - B. Moran (UK)

PLENARY
ROOM

> **CO22** - Can we cure patients with abdominal Desmoplastic Small Round Cell Tumor? Results of a retrospective multicentric study on 100 patients.

C. Honoré, J.B. Delhorme, E. Nassif, G. Ferron, E. Bompas, J. Adam, O. Glehen, A. Italiano, F. Bertucci, D. Orbach, A. Lechesne, J.Y. Blay, C. Chevreau, O. Mir (France).

> **CO23** - Recurrence pattern and timing of pseudomyxoma peritonei after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

F. Mercier (France), F. Dagbert (Canada), M. Pocard (France), D. Goéré (France), F. Quenet (France), R. Wernert (France), F. Dumont (France), C. Brigand (France), G. Passot (France), O. Glehen (France).

> **CO24** - Multicystic peritoneal mesothelioma- outcome analysis of to the PSOGI international registry.

E. Nizri (Italy), O. Glehen (France), D. Goere (France), D. Baratti (Italy), D. Morris (Australia), M. De Simone (Italy), Y. Yonemura (Japan), J.J. Tuech (France), J.M. Bereder (France), V. Kepenkian (Japan), S. Kusamura (Japan), M. Deraco (Italy).

> **CO25** - The association of Transcriptional Oncogenes Signature, Cellular Behavior and Stromal Score may predict outcome of PMP patients despite histopathological classification and may guide treatment options and follow up.

M. Vaira, C. Isella, M. Robella, E. Medico, M. De Simone (Italy).

09h20 **In practice**

Chairmen: J. Esquivel (USA) - D. Morris (USA)

1. New classification for peritoneal pseudomyxoma

Speaker: P. Dartigues (France)

2. LAMN, surveillance or HIPEC?

Speaker: J. Baumgartner (USA)

09h50 **Take home message and vote**

Towards a consensus for treatment of non resectable malignant peritoneal mesothelioma.

Chairmen: M. Deraco (Italy) - G. Freyer (France)

Speaker: M. Ducreux (France)

10h15 **BREAK - VISIT POSTERS AND EXHIBITS**

10h45 **Consensus statement for Peritoneal Mesothelioma and Pseudomyxoma peritonei**

11h15 **Recent results of the randomized clinical trials and futures for primary malignancies**

Chairmen: D. Baratti (Italy) - B. Moran (UK) - F. Quenet (France)

12h15 **LUNCH - VISIT POSTERS AND EXHIBITS**

13h30 **Satellite Symposium**

Organized by **AstraZeneca**



Precision medicine starts from the surgery in ovarian cancer

1. Theranostic approach in ovarian cancer

Speaker: B. You (France)

2. Practice changing surgery studies: any impact on patient management by PARPI?

Speaker: C. Pomet (France)

14h30 Selected videos and free papers*Chairmen: C. Eveno (France) - J. Huguenin (Brazil)***> V5 - Laparoscopic HIPEC via a single approach.***F. Dumont (France), E. Thibaudeau (France)***> V6 - Laparoscopic cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (crs/hipec) for perforated low grade appendiceal mucinous neoplasm (Iamn 2).***E. Parkin, Ms. Wilson, St. O'Dwyer, Ag. Renehan, C. Selvasekar, O. Aziz (UK)***> CO27 - Long term outcomes of laparoscopic HIPEC in low grade pseudomyxoma and multicystic mesothelioma.***F. Mercier, J. Guedj, M. Alyami, D. Vaudoyer, V. Kepenekian, P. Rousset, G. Passot, O. Glehen (France)***> CO28 - Cytoreduction and HIPEC vs. Cytoreduction alone in diffuse malignant peritoneal mesothelioma: A propensity score analysis of the PSOGI registry.***S. Kusamura (Italy), F. Barretta (Italy), P.H. Sugarbaker (USA), E.A. Levine (USA), O. Glehen(France), D.L. Morris (Australia), M. De Simone (Italy), D. Goere (France), B. Moran (UK), Y. Yonemura (Japan), L. Villeneuve (France), D. Baratti (Italy), M. Deraco (Italy).***> CO29 - Palliative Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) provides durable disease and ascites control for patients with appendiceal adenocarcinoma with extensive peritoneal metastases.***J. Lindberg, S. Rafeeq, A. Khazi, P. Kanaby, O. Shayeb, J. Al Khafaji, K. Beaty, P. Mansfield, R. Royal, K. Fournier (USA).***15h10 Debates about pre - and / or post systemic chemotherapy associated to HIPEC for colorectal peritoneal metastases***Chairmen: B. Rau (Germany) - Y. Li (China)***1. Pro systemic chemotherapy***Speaker: C. Eveno (France)***2. Contra systemic chemotherapy***Speaker: I. De Hingh (The Netherlands)***15h40 Take home message:****Management of per and postoperative intraperitoneal bleeding***Chairmen: C. Brigand (France) - P. Piso (Germany)**Speaker: PH. Sugarbaker (USA)*

PARALLEL SESSION

ROOM
10114h30 **Anesthesiology and intensive care for HIPEC***Chairmen: E. Gayat (France) - V. Billard (France)*

1. Key issues of preoperative assessment and prehabilitation.
Speaker: E. Gayat (France)
2. Analgesia after HIPEC: epidural, systemic OFA or opioid based analgesia
Speaker: F. Wallet (France)
3. Fluid load, monitoring and cardiac output optimisation during HIPEC
Speaker: J. Bell (UK)
4. Metabolic changes during HIPEC and management
Speaker: J. Raft (France)
5. Postoperative outcome and management:
Speaker: B. Chousterman (France)

16h00 **BREAK - VISIT POSTERS AND EXHIBITS**16h30 **Anesthesia – Early recovery – Preoperative preparation – Nutrition
Free papers***Chairmen: G. Passot (France) – F. Mohamed (UK)*

> **CO35** - Renal protection with sodium thiosulfate during hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin.

N. Laplace, V. Kepenekian, F. Mercier, A. Friggeri, N. Bakrin, G. Passot, D. Vaudoyer, O. Glehen (France).

> **CO36** - A Randomised Controlled Trial to Compare Administration of Prothrombin Complex Concentrate with Standard Haemostasis Management in Adult Patients Undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) Requiring Massive Transfusion.
M.S. Alshahrani, O.M. Fisher, S.J. Ho, N.A. Alzahrani, W. Liauw, D.L. Morris (Australia).

> **CO37** - Hyperthermic intraperitoneal chemotherapy enhances blood coagulation.

M. Tuovila, T. Erkinaro, H. Takala, E.R. Savolainen, P. Laurila, P. Ohtonen (Finland).

> **CO38** - Impact of Prehabilitation on Patients undergoing Cytoreductive Surgery and HIPEC.

D. Cortes-Guiral, J.R. Torres-Alfonso, J. Barambio, I. Lopez-Rojo, I. Guijo-Castellano, A. Badia, H. Guadalajara, S. Jimenez De Los Galanes, D. Garcia-Olmo (Spain).

17h10 **Satellite Symposium:****Debates: Hyperthermia: yes or not?***Chairmen: I. de Hingh (The Netherlands) - F. Quenet (France)*

1. Pro hyperthermia:

Speaker: D. Morris (Australia)

2. Contra hyperthermia:

*Speaker: W. Ceelen (Belgium)*17h45 **Clinical cases “from the less to the more experienced surgeons”***Chairmen: JB. Delhorme (France) - M. Gelli (France)*PLENARY
ROOM

PARALLEL SESSION

ROOM
10116h30 **Intraperitoneal Drugs and Pharmacology - free papers***Chairmen: N. Bakrin (France) - K. Van der Speeten (The Netherlands)*

> **CO30** - Standardization of intraperitoneal chemotherapy: pharmacologic guidance towards an optimal dosimetry method in colorectal peritoneal surface malignancy treatment.

L. Lemoine (Belgium), E. Thijssen (Belgium), R. Carleer (Belgium), P. Sugarbaker (USA), K. Van Der Speeten (Belgium).

> **CO31** - Pharmacological effects of carrier fluids on the hyperthermic intraperitoneal chemotherapy using oxaliplatin in vitro and in vivo.

E.J. Park, K.S. Park, S.J. Hwang, S.H. Baik (Korea).

> **CO32** - There is no difference in pharmacologic advantage between BSA-based and concentration-based HIPEC after CRS in colorectal peritoneal carcinomatosis' treatment: an experimental study.

L. Lemoine (Belgium), E. Thijssen (Belgium), R. Carleer (Belgium), P. Sugarbaker (USA), K. Van Der Speeten (USA).

> **CO33** - Phase I study assessing safety of intraperitoneal chemotherapy in the neoadjuvant treatment of peritoneal carcinomatosis of colorectal origin (NIPOX).

O. Sgarbura, E. Samalin, S. Poujol, S. Carrere, F. Portales, M.H. Pissas, M. Al Hosni, F. Bibeau, M. Ychou, F. Quenet (France).

> **CO34** - Phase 1 study of pressurized intraperitoneal aerosol chemotherapy (PIPAC) with oxaliplatin for peritoneal carcinomatosis.

G. Kim, H.L. Tan, E. Chen, S.C. Teo, C. Jang, B. Lieske, C.E. Chee, R. Sundar, L. Wang, A. Shabbir, W.P. Yong, J. So (Singapore).

20h00 **CONGRESS BANQUET** (Registration required)

NURSING AND ALLIED HEALTH SESSIONS DAY

ROOM
201

08h30 PARALLEL SESSIONS

08h45 **Invited conference**
Cytoreductive surgery and HIPEC: current indications and issues

09h15 **Free session 1:**
Modalities of IP chemotherapy and the related current issues

10h15 BREAK - VISIT POSTERS AND EXHIBITS

10h45 **Round table 1:**
The nurse in the OR: education practices all around the globe

11h30 **Free session 2:**
Allied professionals roles and peritoneal carcinomatosis treatment

12h15 LUNCH - VISIT POSTERS AND EXHIBITS

13h30 **Invited conference**
Checklist and prevention of accidents in the operative room

14h15 **Free session 3:**
The management of HIPEC patients in the OR

15h00 **Round table 2:**
Caregivers and working environment safety: practices around the globe

16h00 BREAK - VISIT POSTERS AND EXHIBITS

16h30 **Free session 4:**
PIPAC – new challenges in the OR and in the surgery department

17h30 **CLOSING REMARKS: THE ORGANIZING COMMITTEE -
ORGANIZERS OF BEIJING 2020**

Tuesday, September 11th

07h00 **Registration**

07h30 **Meet the professor**

**1. How to set up a national HIPEC program
(Instances and registries)**

A. Bhatt (India) - F. Dumont (France) - C. Quadros (Brazil)

ROOM
201

2. How to set up a national PIPAC program

N. Bakrin (France) - M. Hübner (Switzerland) - M. Alyami (France)

ROOM
232

**3. New technology to detect non visible peritoneal deposits
(indocyanine green ...)**

J. Esquivel (USA) - M. Gelli (France) - G. Liberale (Belgium)

ROOM
233

**4. Requirement for stoma after complete pelvic
peritonectomy with rectosigmoid colon resection and HIPEC**

C. Arvieux (France) - O. Glehen (France) - PH. Sugarbaker (USA)

ROOM
234

5. Enhanced recovery and HIPEC

D. Goéré (France) - F. Mohamed (UK) - G. Passot (France)

ROOM
269

08h30 **Peritoneal carcinomatosis from ovarian carcinoma free papers**

Chairmen: L. Gladieff (France) - A. Fagotti (Italy)

PLENARY
ROOM

> **CO39** - Health-related quality of life after Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for stage III ovarian cancer: results of the phase III OVHIPEC study.

S. Koole (The Netherlands), J. Kieffer (The Netherlands), K. Sikorska (The Netherlands), J. Schagen Van Leeuwen (The Netherlands), H. Schreuder (The Netherlands), R. Hermans (The Netherlands), I. De Hingh (The Netherlands), J. Van Der Velden (The Netherlands), H. Arts (The Netherlands), L. Massuger (The Netherlands), A. Aalbers (The Netherlands), V. Verwaal (Denmark), K. Van De Vijver (Belgium), G. Sonke (The Netherlands), W. Driel (The Netherlands), N. Aaronson (The Netherlands).

> **CO40** - A phase I trial assessing the feasibility of debulking surgery followed by cisplatin-based hyperthermic Intraperitoneal chemotherapy and intraperitoneal bi-monthly nivolumab in advanced ovarian carcinoma. The ICONIC study.

G. Freyer, C. Sajous, B. You, J. Lopez, D. Dayde, N. Medeghri, G. Witold, O. Glehen (France).

> **CO41** - Morbidity and mortality after a first cytoreduction with or without HIPEC in ovarian cancer IIIC-IV. Preliminary Results of the Prospective and Randomized Clinical Trial.

A. González Gil, Á. J. Gómez Ruiz, E. Gil Gómez, J. Gil Martínez, P. Cascales Campos (Spain).

> **CO42** - Time to adjuvant chemotherapy and impact on survival in advanced ovarian malignancies: Indian Society of Peritoneal Surface Malignancy (ISPSM) collaborative group study.

S. Zaveri, S. Somashekhar, K. Ashwin, C. Rohit Kumar, Y. Ramya (India).

> **CO43** - A comparison of outcomes following total and selective peritonectomy performed at the time of interval cytoreductive surgery for advanced serous epithelial ovarian, fallopian tube and primary peritoneal cancer- A study by INDEPSO.

A. Bhatt, S. Sinukumar, S. Zaveri, F. Rajan, D. Damodaran, P. Kammer, S. Mehta (India).

09h20 **Controversial on the randomized clinical trials and futures for HIPEC in peritoneal carcinomatosis from ovarian cancer**

Chairmen: JM. Classe (France) - G. Freyer (France) - J. Spiliotis (Greece)

› HIPEC as standard or optional in first line treatment

Pro: WJ. Van Driel (The Netherlands)

Contra: G. Freyer (France)

› HIPEC as standard or optional in platine sensitive recurrence

Pro: J. Spiliotis (Greece)

Contra: A. Fagotti (Italy)

› HIPEC as standard or optional in platine resistant recurrence

Pro: N. Bakrin (France)

Contra: JM. Classe (France)

10h35 **Award ceremony**

10h45 **BREAK - VISIT POSTERS AND EXHIBITS**

11h15 **Timing of surgery in peritoneal carcinomatosis from ovarian carcinoma**

Chairman: A. Fagotti (Italy)

Speaker: DS. Chi (USA)

11h40 **Free papers from clinical trials and futures for PIPAC**

Chairmen: M. Pocard (France) - M. Reymond (Germany)

> V6 - Pipac: 8 key points for a good practice.

G. Mariano, M. Pocard, C. Eveno (France)

> CO44 - Pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy with VEGF-A, evaluation of safety and feasibility.

M. Siebert, M. Alyami, F. Mercier, C. Gallice, L. Villeneuve, N. Bakrin, O. Glehen (France).

> CO45 - Is a single laparoscopic biopsy enough to determine the regression grading score of peritoneal metastases after palliative chemotherapy?

W. Solass, F. Kurtz, F. Struller, A. Staebler, H. Bösmüller, F. Fend (Germany).

> CO46 - Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in resected high-risk colon cancer patients.

M. Graversen, S. Detlefsen, C. Fristrup, P. Pfeiffer, M. Bau Mortensen (Denmark).

> CO47 - Anesthesia in toxic spaces: PIPAC Pressurized intraperitoneal aerosol chemotherapy.

A. Rouche, B. Pache, F. Grass, M. Hubner, N. Demartines, C. Blanc (Switzerland).

> CO48 - Description of ATM 220® technology and granulometric characterization of the aerosol applied for Hyperthermic Intracavitary Nanoaerosol Therapy (HINAT).

S. Reck, V. Khosrawipour, F.J. Weinreich, K. Schenke-Layland, M.A. Reymond (Germany).

12h45 **Beijing PSOGI 2020**

13h00 **END OF THE MEETING**

